Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

18.222.35.177
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Alagille Syndrome
Conference Roundup

Natural history data may be helpful in assessing outcomes in ALGS

Posted on

Using natural history data from prospective longitudinal databases may help determine the potential impact of investigational treatments on patients with Alagille Syndrome (ALGS), according to a study presented at The Liver Meeting 2021.

According to presenter, Benjamin Shneider, MD, prolonged treatment with placebo as a comparison is difficult in patients with cholestatic liver diseases. Shneider et al investigated whether determining outcomes in ALGS without investigational treatment was feasible by applying clinical trial-based selection criteria to a prospective longitudinal observational study.

Researchers used the eligibility criteria from a randomized trial of maralixibat in patients with ALGS (ITCH; CT02057692) on participants in the Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC; NCT00571272). Frequency weighting was applied to the LOGIC cohort for analysis due to a higher number of participants < 2 years of age compared to the ITCH cohort.

-Advertisement-
-Advertisement-

There were 252 children with ALGS and their native liver enrolled in LOGIC, of which 59 were not enrolled in ITCH and met eligibility criteria with ≥1 follow up. 

The weighted cohort was well-matched to the baseline ITCH cohort. Statistically and clinically significant reductions in pruritus were seen at 1- and 2-year follow-up.

At 1 year, there was a 59% reduction in clinician scratch scale and at 2 years, that increased to 73%. During this time there were no major changes in the use of anti-pruritic agents. After 2 years, 24% of the cohort had no scratching and 31% had mild scratching. Platelet count decreased significantly during the 2-year follow-up, while height, but not weight z-score, increased significantly during follow-up.

“This clinical data may be useful in contextualizing the findings of clinical trials,” the authors concluded.

Reference
Shneider B, et al. Utilization of Multi-Center Prospective Longitudinal Databases to Inform Clinical Trials in Rare Diseases- Examination of Cholestatic Liver Disease in Alagille syndrome (ALGS). Presented at: The Liver Meeting 2021.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-